Skip to main content
Year archive

BioLineRx Ltd. — 2023 filings

All 63 regulatory filings released by BioLineRx Ltd. (BLRX) in 2023, sourced directly from the official regulator.

63 Filings
2023 Period
2023 filings (63)
Filing Released Lang
FORM F-3-REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
Capital/Financing Update
2023-12-31 English
FORM F-3-REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
Report Publication Announcement
2023-12-31 English
FORM S-8-registration of Ordinary Shares to be issued under the Plan
Capital/Financing Update
2023-12-31 English
FORM S-8-registration of Ordinary Shares to be issued under the Plan
Report Publication Announcement
2023-12-31 English
S-8
Registration Form
2023-12-29 English
F-3
Regulatory Filings
2023-12-29 English
6-K
Foreign Filer Report
2023-12-21 English
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease
Regulatory Filings
2023-12-21 English
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease
Report Publication Announcement
2023-12-21 English
Appointment of Gal Cohen to its Board of Director
Board/Management Information
2023-12-12 English
Appointment of Gal Cohen to its Board of Director
Board/Management Information
2023-12-12 English
6-K
Foreign Filer Report
2023-12-12 English
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
Interim / Quarterly Report 9M 2023
2023-11-20 English
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
Earnings Release Q3 2023
2023-11-20 English
6-K
Foreign Filer Report
2023-11-20 English
SC 13D
Major Shareholding Notification
2023-10-26 English
6-K
Foreign Filer Report
2023-10-12 English
BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment
Regulatory Filings
2023-10-12 English
BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment
Report Publication Announcement
2023-10-12 English
6-K
Foreign Filer Report
2023-09-28 English
BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (PDAC)
Regulatory Filings
2023-09-28 English
BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (PDAC)
Report Publication Announcement
2023-09-28 English
6-K
Foreign Filer Report
2023-09-11 English
BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Pat
Regulatory Filings
2023-09-11 English
BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Pat
Report Publication Announcement
2023-09-11 English
6-K
Foreign Filer Report
2023-08-30 English
Second Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
Interim / Quarterly Report Q2 2023
2023-08-30 English
Second Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
Report Publication Announcement H1 2023
2023-08-30 English
6-K
Foreign Filer Report
2023-08-30 English
Results of Annual General Meeting held on August 7, 2023
AGM Information
2023-08-09 English
Results of Annual General Meeting held on August 7, 2023
AGM Information
2023-08-09 English
6-K
Foreign Filer Report
2023-08-08 English
6-K
Foreign Filer Report
2023-07-17 English
BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase; Combination Trial Includes Investi
Regulatory Filings
2023-07-17 English
BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase; Combination Trial Includes Investi
Regulatory Filings
2023-07-17 English
Immediate Report of Meeting to be held on August 7, 2023, proxy statement
Proxy Solicitation & Information Statement
2023-06-23 English
Immediate Report of Meeting to be held on August 7, 2023, proxy statement
AGM Information
2023-06-23 English
Immediate Report of Meeting to be held on August 7, 2023, proxy statement
AGM Information
2023-06-23 English
6-K
Foreign Filer Report
2023-06-23 English
6-K
Foreign Filer Report
2023-05-24 English
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
Interim / Quarterly Report Q1 2023
2023-05-24 English
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
Report Publication Announcement
2023-05-24 English
Regains Compliance with Nasdaq Minimum Bid Price Requirement
Regulatory Filings
2023-04-27 English
Regains Compliance with Nasdaq Minimum Bid Price Requirement
Report Publication Announcement
2023-04-27 English
6-K
Foreign Filer Report
2023-04-25 English
6-K
Foreign Filer Report
2023-04-17 English
BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide and G-CSF in Stem Cell Mobilization for Autologous Transplantation in Multiple My
Regulatory Filings
2023-04-17 English
BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide and G-CSF in Stem Cell Mobilization for Autologous Transplantation in Multiple My
Report Publication Announcement
2023-04-17 English
FORM 20-F For the fiscal year ended December 31, 2022
Regulatory Filings
2023-03-22 English
FORM 20-F For the fiscal year ended December 31, 2022
Report Publication Announcement
2023-03-22 English
20-F
Annual Report FY 2022
2023-03-22 English
6-K
Foreign Filer Report
2023-03-22 English
BioLineRx Reports 2022 Financial Results and Recent Corporate and Portfolio Updates
Earnings Release FY 2022
2023-03-22 English
BioLineRx Reports 2022 Financial Results and Recent Corporate and Portfolio Updates
Report Publication Announcement
2023-03-22 English
6-K
Foreign Filer Report
2023-03-06 English
BioLineRx Announces Clinical Trial Collaboration with Washington University School of Medicine to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cel
Regulatory Filings
2023-03-06 English
BioLineRx Announces Clinical Trial Collaboration with Washington University School of Medicine to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cel
Report Publication Announcement
2023-03-06 English
S-8
Registration Form
2023-01-20 English
6-K
Foreign Filer Report
2023-01-04 English
BioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer
Regulatory Filings
2023-01-04 English
BioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer
Board/Management Information
2023-01-04 English
BioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer
Regulatory Filings
2023-01-04 English
BioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer
Board/Management Information
2023-01-04 English